Wunchana Seubwai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6829067/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. Canadian Journal of Diabetes, 2021, 45, 282-290.	0.8	8
2	High glucoseâ€ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8. Cancer Science, 2021, 112, 254-264.	3.9	7
3	High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma. Life Sciences, 2021, 271, 119114.	4.3	12
4	FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients. Heliyon, 2021, 7, e06846.	3.2	7
5	High glucose: an emerging association between diabetes mellitus and cancer progression. Journal of Molecular Medicine, 2021, 99, 1175-1193.	3.9	38
6	Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis. Molecules, 2021, 26, 3105.	3.8	6
7	FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sciences, 2021, 286, 120072.	4.3	9
8	NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. Life Sciences, 2020, 262, 118548.	4.3	9
9	Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clinica Chimica Acta, 2020, 510, 142-149.	1.1	12
10	Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines. Anticancer Research, 2020, 40, 5115-5124.	1.1	23
11	Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Human Cell, 2020, 33, 695-708.	2.7	69
12	Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma. Oncology Letters, 2019, 17, 5275-5282.	1.8	11
13	Overexpression of HexCer and LacCer containing 2-hydroxylated fatty acids in cholangiocarcinoma and the association of the increase of LacCer (d18:1-h23:0) with shorter survival of the patients. Glycoconjugate Journal, 2019, 36, 103-111.	2.7	12
14	Blocking of methionine aminopeptidase-2 by TNP-470 induces apoptosis and increases chemosensitivity of cholangiocarcinoma. Journal of Cancer Research and Therapeutics, 2019, 15, 148.	0.9	3
15	Activation of Vimentin Is Critical to Promote a Metastatic Potential of Cholangiocarcinoma Cells. Oncology Research, 2018, 26, 605-616.	1.5	15
16	Artesunate and chloroquine induce cytotoxic activity on cholangiocarcinoma cells via different cell death mechanisms. Cellular and Molecular Biology, 2018, 64, 113-118.	0.9	1
17	Targeting hexokinase II as a possible therapy for cholangiocarcinoma. Biochemical and Biophysical Research Communications, 2017, 484, 409-415.	2.1	32
18	High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Scientific Reports. 2017. 7. 43842.	3.3	75

2

WUNCHANA SEUBWAI

#	Article	IF	CITATIONS
19	Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. Histology and Histopathology, 2017, 32, 503-510.	0.7	27
20	Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-Äß. Anticancer Research, 2017, 37, 115-124.	1.1	48
21	Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells. Oncology Research, 2016, 23, 21-28.	1.5	29
22	High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Scientific Reports, 2016, 6, 18995.	3.3	58
23	Establishment and characterization of a novel human cholangiocarcinoma cell line with high metastatic activity. Oncology Reports, 2016, 36, 1435-1446.	2.6	24
24	Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-κB. Scientific Reports, 2016, 6, 27853.	3.3	43
25	Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. Materials Science and Engineering C, 2016, 60, 411-415.	7.3	28
26	Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. International Journal of Oncology, 2015, 47, 398-410.	3.3	61
27	Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma. Cancer Epidemiology, 2015, 39, 274-278.	1.9	30
28	Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. Clinical Biochemistry, 2015, 48, 668-673.	1.9	27
29	Aberrant Expression of NF-κB in Liver Fluke Associated Cholangiocarcinoma: Implications for Targeted Therapy. PLoS ONE, 2014, 9, e106056.	2.5	37
30	Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines. International Journal of Oncology, 2014, 45, 1159-1166.	3.3	9
31	Establishment of an Allo-Transplantable Hamster Cholangiocarcinoma Cell Line and Its Application for In Vivo Screening of Anti-Cancer Drugs. Korean Journal of Parasitology, 2013, 51, 711-717.	1.3	11
32	22â€Oxaâ€1,25â€dihydroxyvitamin D ₃ efficiently inhibits tumor growth in inoculated mice and primary histoculutre of cholangiocarcinoma. Cancer, 2010, 116, 5535-5543.	4.1	22
33	Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NFâ€ÎºB. Cancer Science, 2010, 101, 1590-1595	3.9	69
34	Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma. Cancer, 2007, 109, 2497-2505.	4.1	45